Harrow HROW 深 滬
等待開盤 08-21 09:30:00 美东时间
42.06
+0.420
+1.01%
華盛通- 最 高42.71
- 今 開41.64
- 成交量 45.01万股
- 最 低 41.24
- 昨 收 41.64
- 總市值 157.67万
- 52周最高 54.85
- 市盈率 靜 --
- 換手率 1200.57%
- 52周最低 28.5401
- 委 比 -72.26%
- 總股本 3.75万
- 歷史最高 59.23
- 量 比 0.77
- 振 幅 3.53%
- 歷史最低 3.33
- 每 手 1
- 風險率 5.42%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Harrow Reports Statistically Significant Results Favoring IHEEZO In Intravitreal Injection Study
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective, randomized, contralateral-eye study evaluating IHEEZO® (chloroprocaine hydrochloride ophthalmic gel) 3%, an ophthalmic gel indicated for ocular s...
08-20 19:04
Harrow Affirms FY2026 Sales Guidance of $350.000M-$365.000M vs $348.468M Est
Harrow (NASDAQ:HROW) affirms FY2026 sales outlook from $350.000 million-$365.000 million to $350.000 million-$365.000 million vs $348.468 million estimate.
08-11 04:09
Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease
Harrow has agreed to acquire TYRVAYA, a nasal spray for dry eye disease, from Viatris for up to $100 million. TYRVAYA, approved in the U.S., China, and Taiwan, offers a different mechanism of action compared to Harrow's VEVYE, addressing tear production without eye drop side effects. The acquisition expands Harrow's dry eye portfolio, providing more treatment options for patients and enhancing its market position.
08-06 11:00
美股大行评级 | 富国银行上调亚马逊目标价从313美元升至322美元；潜在涨幅370.99%！HC Wainwright上调Greenwich LifeSciences目标价至69美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Greenwich LifeSciences"买入"评级，目标价从50美元升至69美元；高盛：维持Taysha Gene Therapies"买入"评级，目标价从11美元升至13美元
07-22 11:35
BTIG Reiterates Buy on Harrow, Maintains $63 Price Target
BTIG analyst Thomas Shrader reiterates Harrow (NASDAQ:HROW) with a Buy and maintains $63 price target.
07-21 17:51
Harrow Highlights Growing Clinical Evidence Supporting IHEEZO® and BYOOVIZ® at ASRS 2026 Annual Meeting
Harrow announced the presentation of three studies supporting IHEEZO® and BYOOVIZ® at the ASRS 2026 Annual Meeting. The studies expand clinical and real-world evidence for Harrow's retina portfolio. IHEEZO showed promising trends in reducing post-procedure pain and improving patient experience, while BYOOVIZ demonstrated safety and effectiveness in real-world use. Harrow emphasized its commitment to generating quality evidence to support long-ter...
07-20 11:00
8 Health Care Stocks With Whale Alerts In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders often look for circumstances when the market estimation of an option diverges away fro...
07-07 01:35
Harrow Announces Commercial Launch Of BYOOVIZ, FDA-Approved Biosimilar Referencing LUCENTISi And Developed By Samsung Bioepis
Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab) and developed by Samsung Bioepis Co., Ltd. The launch follows Har...
07-01 19:02
Harrow Adds Another Piece To Ophthalmology Strategy
Harrow Inc. (NASDAQ:HROW) on Wednesday announced the relaunch of VERKAZIA (cyclosporine ophthalmic emulsion) 0.1%, a prescription treatment for vernal keratoconjunctivitis (VKC), a serious allergic eye condition that primarily affects children. The eye care company said the move reflects its continu...
06-11 23:42
Alpha Buying: When CEOs and CFOs Buy Together
The market remains obsessed with headlines, politics, tariffs, inflation scares...
05-29 00:18
